RESUMO
For a structural health monitoring (SHM) system, the operational functionality of sensors is critical for successful implementation of a damage identification process. This study presents experimental and analytical investigations on sensor fault diagnosis for impedance-based SHM using the piezoelectric interface technique. Firstly, the piezoelectric interface-based impedance monitoring is experimentally conducted on a steel bolted connection to investigate the effect of structural damage and sensor defect on electromechanical (EM) impedance responses. Based on the experimental analysis, sensor diagnostic approaches using EM impedance features are designed to distinguish the sensor defect from the structural damage. Next, a novel impedance model of the piezoelectric interface-driven system is proposed for the analytical investigation of sensor fault diagnosis. Various parameters are introduced into the EM impedance formulation to model the effect of shear-lag phenomenon, sensor breakage, sensor debonding, and structural damage. Finally, the proposed impedance model is used to analytically estimate the change in EM impedance responses induced by the structural damage and the sensor defect. The analytical results are found to be consistent with experimental observations, thus evidencing the feasibility of the novel impedance model for sensor diagnosis and structural integrity assessment. The study is expected to provide theoretical and experimental foundations for impedance monitoring practices, using the piezoelectric interface technique, with the existence of sensor faults.
RESUMO
Recently developed therapeutic approaches for the treatment of Huntington's disease (HD) require preclinical testing in large animal models. The minipig is a suitable experimental animal because of its large gyrencephalic brain, body weight of 70-100â kg, long lifespan, and anatomical, physiological and metabolic resemblance to humans. The Libechov transgenic minipig model for HD (TgHD) has proven useful for proof of concept of developing new therapies. However, to evaluate the efficacy of different therapies on disease progression, a broader phenotypic characterization of the TgHD minipig is needed. In this study, we analyzed the brain tissues of TgHD minipigs at the age of 48 and 60-70â months, and compared them to wild-type animals. We were able to demonstrate not only an accumulation of different forms of mutant huntingtin (mHTT) in TgHD brain, but also pathological changes associated with cellular damage caused by mHTT. At 48â months, we detected pathological changes that included the demyelination of brain white matter, loss of function of striatal neurons in the putamen and activation of microglia. At 60-70â months, we found a clear marker of neurodegeneration: significant cell loss detected in the caudate nucleus, putamen and cortex. This was accompanied by clusters of structures accumulating in the neurites of some neurons, a sign of their degeneration that is also seen in Alzheimer's disease, and a significant activation of astrocytes. In summary, our data demonstrate age-dependent neuropathology with later onset of neurodegeneration in TgHD minipigs.
Assuntos
Doença de Huntington/patologia , Degeneração Neural/patologia , Envelhecimento/patologia , Animais , Animais Geneticamente Modificados , Biomarcadores/metabolismo , Índice de Massa Corporal , Núcleo Caudado/patologia , Núcleo Caudado/ultraestrutura , Modelos Animais de Doenças , Feminino , Genótipo , Humanos , Proteína Huntingtina/metabolismo , Masculino , Córtex Motor/patologia , Córtex Motor/ultraestrutura , Bainha de Mielina/metabolismo , Agregados Proteicos , Suínos , Porco Miniatura , Redução de Peso , Substância Branca/patologia , Substância Branca/ultraestruturaRESUMO
Huntington's disease (HD) is a monogenic, progressive, neurodegenerative disorder with currently no available treatment. The Libechov transgenic minipig model for HD (TgHD) displays neuroanatomical similarities to humans and exhibits slow disease progression, and is therefore more powerful than available mouse models for the development of therapy. The phenotypic characterization of this model is still ongoing, and it is essential to validate biomarkers to monitor disease progression and intervention. In this study, the behavioral phenotype (cognitive, motor and behavior) of the TgHD model was assessed, along with biomarkers for mitochondrial capacity, oxidative stress, DNA integrity and DNA repair at different ages (24, 36 and 48â months), and compared with age-matched controls. The TgHD minipigs showed progressive accumulation of the mutant huntingtin (mHTT) fragment in brain tissue and exhibited locomotor functional decline at 48â months. Interestingly, this neuropathology progressed without any significant age-dependent changes in any of the other biomarkers assessed. Rather, we observed genotype-specific effects on mitochondrial DNA (mtDNA) damage, mtDNA copy number, 8-oxoguanine DNA glycosylase activity and global level of the epigenetic marker 5-methylcytosine that we believe is indicative of a metabolic alteration that manifests in progressive neuropathology. Peripheral blood mononuclear cells (PBMCs) were relatively spared in the TgHD minipig, probably due to the lack of detectable mHTT. Our data demonstrate that neuropathology in the TgHD model has an age of onset of 48â months, and that oxidative damage and electron transport chain impairment represent later states of the disease that are not optimal for assessing interventions.This article has an associated First Person interview with the first author of the paper.